Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial of Durvalumab (Medi4736) Plus Tremelimumab With Concurrent Radiotherapy in Patients With Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach

Next Previous
Trial Profile

Phase II Trial of Durvalumab (Medi4736) Plus Tremelimumab With Concurrent Radiotherapy in Patients With Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Acronyms IMMUNOPRESERVE-SOGUG; INMUNOPRESERVE; SOGUG

    • Most Recent Events

    • 08 Jun 2021 Results assessing efficacy and safety of durvalumab plus tremelimumab with concurrent radiotherapy in patients with localized muscle invasive bladder cancer, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Feb 2021 Status changed from recruiting to active, no longer recruiting.
    • 31 May 2020 According to trial design presented at the 56th Annual Meeting of the American Society of Clinical Oncology, second stage accrual began in December 2019.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top